AllSci News
Larimar Therapeutics raises USD 100m in upsized underwritten public offering
U.S.-based Larimar Therapeutics, Inc. (Nasdaq: LRMR) announced the pricing of an upsized underwritten public offering of common stock with aggregate gross...
FDA approves Bristol Myers Squibb's Opdivo for previously untreated advanced classical Hodgkin lymphoma
On March 20, 2026, the US FDA approved Opdivo (nivolumab) in combination with doxorubicin, vinblastine, and dacarbazine (AVD) for adult and pediatric...
Eli Lilly's retatrutide delivers significant A1C and weight reductions in Phase III type 2 diabetes trial
Eli Lilly and Company (NYSE: LLY) announced positive topline results from TRANSCEND-T2D-1, the first Phase III trial evaluating retatrutide in adults with...
JSKN027 First-in-Human Trial Targets Advanced Solid Tumors at Peking University
Novel Cancer Therapy JSKN027 Enters First-in-Human Clinical Trial
Beam Therapeutics' BEAM-302 shows sustained protective AAT levels in alpha-1 antitrypsin deficiency trial
Beam Therapeutics reported updated clinical data from its ongoing Phase I/II trial of BEAM-302 in alpha-1 antitrypsin deficiency, showing that a single 60...
AstraZeneca's tozorakimab meets primary endpoint in both Phase III COPD exacerbation trials
AstraZeneca (LSE/STO/NYSE: AZN) reported that tozorakimab, its anti-IL-33 monoclonal antibody, met the primary endpoint in both the OBERON and TITANIA Phase...
Nasus Pharma raises USD 15m in private placement financing
Nasus Pharma Ltd. (NYSE: NSRX) announced a USD 15.0 million private placement financing on February 10, 2026, targeting the advancement of its intranasal...
EpiBiologics Launches Phase 1 Trial of EPI-326 EGFR-Degrading Bispecific Antibody in NSCLC and HNSCC
EpiBiologics has posted a Phase 1 clinical trial (NCT07462377) for EPI-326, a tissue-selective bispecific antibody targeting EGFR in patients with locally...
FDA approves Rhythm Pharmaceuticals' Imcivree for acquired hypothalamic obesity in adults and children
The US FDA has approved an expanded indication for IMCIVREE (setmelanotide), developed by Rhythm Pharmaceuticals, to treat acquired hypothalamic obesity in...
BridgeBio's infigratinib shows statistically significant Phase 3 results in achondroplasia body proportionality
BridgeBio Pharma announced positive topline results from PROPEL 3, a global Phase III pivotal study evaluating oral infigratinib in children with...
FDA Approves Bristol Myers Squibb's Sotyktu for Active Psoriatic Arthritis in Adults
The US FDA has approved Sotyktu (deucravacitinib) for the treatment of adults with active psoriatic arthritis, Bristol Myers Squibb announced on 6 March...
Hansa Biopharma Raises USD 30 Million Convertible Note to Fund Imlifidase US Launch
Lund, Sweden-based Hansa Biopharma AB, a commercial-stage biopharmaceutical company developing immunomodulatory therapies for patients with acute or complex...
Avenue Therapeutics licenses ATX-04 clenbuterol from Duke University for Pompe disease treatment
Avenue Therapeutics, Inc. (OTC: ATXI), a Miami-headquartered specialty pharmaceutical company majority-owned by Fortress Biotech, Inc. (Nasdaq: FBIO),...
AnaCardio and Helsinn secure US patent for AC01 calcium sensitizing heart failure treatment
AnaCardio AB (Sweden), a clinical-stage biopharmaceutical company developing contractile agents for heart failure, and its partner Helsinn Healthcare SA...
Evogene and Queensland University of Technology Partner on AI-Driven Cancer Drug Discovery for Lung Cancer
Evogene Ltd. (Nasdaq: EVGN; TASE: EVGN), a Rehovot, Israel-based computational chemistry company, and the Queensland University of Technology (QUT) in...
The AllSci Brief
Systematic R&D and deal news. Daily.